Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis.

Abstract

The anti-CTLA4 antibody, ipilimumab, has shown clinical activity against melanoma. Diarrhea due to immune-related colitis is the most frequent serious toxicity and, if untreated, may lead to intestinal perforation. Diarrhea treatment guidelines were developed based on clinical experience in over 2000 patients treated with ipilimumab, and these safety… (More)
DOI: 10.1089/cbr.2008.0607

Topics

1 Figure or Table

Slides referencing similar topics